[Uncomplicated urinary tract infections: preserving first-line antimicrobial agents in the updated guidelines].

Antimicrobial resistance (AMR) poses a global public health threat and may result in serious economic consequences. Although the treatment regimens for uncomplicated urinary tract infections (UTIs) have remained largely unchanged, they require continuous monitoring due to increasing antimicrobial resistance. The most recent updates of clinical guidelines for the management of uncomplicated UTIs did not revise the list of first-line antibiotics, since no new oral agents are currently available. Single-dose fosfomycin administration has been shown to be as safe and effective as other antibiotics in the treatment of uncomplicated UTIs in women. Fosfomycin therefore remains an adequate empirical treatment option. However, ongoing surveillance of regional antimicrobial resistance is essential to ensure the rational selection of antibiotics for empirical therapy.